Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity

• Published in: Innovacionnaâ medicina Kubani (Online) no. 4; pp. 6 - 14
• Main Authors: Avagimyan, A. A., Trofimenko, A. I., Sheibani, M., Kakturskiy, L. V., Urazova, O. I., Navasardyan, G. A., Jndoyan, Z. T., Sulashvili, N. V., Gabunia, L. I., Gorgaslidze, N. S., Khamidova, F. M., Martemyanova, L. A., Pogosova, N. V., Sarrafzadegan, N.
• Format: Journal Article
• Language: English; Russian
• Published: Scientific Research Institute, Ochapovsky Regional Clinical Hospital no. 1 15.11.2023
• Subjects: cardiotoxicity; dapagliflozin; oxidative stress; trimetazidine
• ISSN: 2541-9897; 2541-9897
• DOI: 10.35401/2541-9897-2023-8-4-6-14

Background: Data published by task groups of the Ministry of Health of the Russian Federation, the European Society of Cardiology, and other medical associations and institutions show that chemotherapy-induced cardiomyopathy is still a challenging issue that requires further research. Objective: To compare the cardioprotective potential of trimetazidine and dapagliflozin in a rat model of doxorubicin-cyclophospha-mide cardiomyopathy. Materials and methods: Our randomized in vivo experimental study included 80 Wistar female rats. Doxorubicin and cyclophosphamide were administered at a dose of 15 mg/kg and 150 mg/kg, respectively. Trimetazidine (42 mg/kg) and dapagliflozin (14 mg/kg) were additionally administered to groups 3 and 4, respectively. The total duration of the experiment was 14 days. Results: Doxorubicin+cyclophosphamide mode of chemotherapy induces the development of toxic-ischemic cardiomyopathy. The trimetazidine and dapagliflozin administration was accompanied by stabilization of cardiovascular parameters. Comparison of both drugs’ cardioprotective properties revealed a clear advantage of dapagliflozin over trimetazidine, especially in terms of such an important indicator as N-terminal pro-B-type natriuretic peptide. Conclusions: Further research aimed at exploring the cardioprotective potential of dapagliflozin against cardiovascular complications of chemotherapy is justified from a pathogenetic point of view.